Galectin Therapeutics (PHPN) Stock Price & Analysis
PHPN Stock Chart & Stats
- Day’s Range
- EUR 2.84 - EUR 3.08
- 52-Week Range
- EUR 1.61 - EUR 5.80
- Previous Close
- EUR 3.06
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 299.80M
- Enterprise Value
- EUR 432.36M
- Total Cash (Recent Filing)
- EUR 13.27M
- Total Debt (Recent Filing)
- EUR 137.70M
- Price to Earnings (P/E)
- ―
- Beta
- -0.53
- Next Earnings
- Nov 16, 2026 (Est.)
- EPS Estimate
- -0.04
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Debt Reduction
The conversion materially reduces reported debt and interest obligations, strengthening the capital structure from a highly leveraged base. It also reflects continued support from the largest shareholder and may preserve more financial capacity for advancing belapectin programs over the next several quarters.
Improving Loss Trend
Although profitability remains negative, narrower losses versus prior periods indicate some improvement in cost control. If sustained, this trend could slow capital consumption and extend operating flexibility while the company continues developing its clinical-stage pipeline.
Targeted Clinical Pipeline
Galectin Therapeutics has a focused therapeutic strategy built around galectin-3 inhibition, a target implicated in fibrosis, inflammation, and oncology. Concentration on belapectin and related indications can support efficient scientific focus and creates multiple potential development avenues.
Bears Say
No Revenue And Persistent Losses
The absence of revenue means the business currently lacks operating income to fund research and development. Persistent EBIT and net losses leave results dependent on financing or other capital sources, making future progress vulnerable if clinical spending continues without commercial receipts.
Stressed Balance Sheet
Deeply negative equity and debt that is large relative to the asset base indicate a thin capital cushion despite the recent conversion. This structure can constrain strategic flexibility and leaves the company exposed to refinancing, funding, and potential dilution pressures.
Ongoing Cash Burn
Continued negative operating and free cash flow shows that the company is not yet self-funding its activities. Even with improvement from earlier periods, ongoing cash consumption increases reliance on external capital and can limit the pace or breadth of clinical development.
Galectin Therapeutics News
Galectin Therapeutics Adjusts Key NASH Cirrhosis Trial, Resetting Expectations for GALT
Galectin Therapeutics (GALT) ($GALT) announced an update on their ongoing clinical study. Galectin Therapeutics Inc. (GALT) has terminated its seamless Phase 2b/3 study of belapectin in patients with NASH cirrhosis
Galectin Therapeutics Adjusts Key NASH Cirrhosis Trial, Resetting Expectations for GALT
Galectin Therapeutics (GALT) ($GALT) announced an update on their ongoing clinical study. Galectin Therapeutics Inc. (GALT) has terminated its seamless Phase 2b/3 study of belapectin in patients with NASH cirrhosis
PHPN FAQ
What was Galectin Therapeutics’s price range in the past 12 months?
What is Galectin Therapeutics’s market cap?
When is Galectin Therapeutics’s upcoming earnings report date?
How were Galectin Therapeutics’s earnings last quarter?
Is Galectin Therapeutics overvalued?
Does Galectin Therapeutics pay dividends?
What is Galectin Therapeutics’s EPS estimate?
How many shares outstanding does Galectin Therapeutics have?
What happened to Galectin Therapeutics’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Galectin Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Galectin Therapeutics Stock Smart Score
Company Description
Galectin Therapeutics
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Joel Lewis
- Employees
- 9
- Website
- galectintherapeutics.com
- Address
- 4960 Peachtree Industrial Boulevard, Norcross, GA, 30071, US
Galectin Therapeutics (PHPN) Earnings & Revenues
PHPN Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 6 | 13 |
| Technical Analysis | 2 | 6 | 2 |
| Moving Averages | 1 | 0 | 11 |
